Roche Holding AG and its US partner, ImmunoGen Inc, said that interim results from a Phase 2 study of their antibody-drug conjugate, trastuzumab-DM1, showed a better response rate in women with metastatic breast cancer, than with a comparator. ---Subscribe to MedNous to access this article--- Company News
